Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Change in Accured Expenses (2019 - 2025)

Immunovant filings provide 7 years of Change in Accured Expenses readings, the most recent being -$7.0 million for Q1 2025.

  • Quarterly Change in Accured Expenses fell 145.42% to -$7.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $255000.0 through Mar 2025, down 81.1% year-over-year, with the annual reading at $255000.0 for FY2025, 81.1% down from the prior year.
  • Change in Accured Expenses hit -$7.0 million in Q1 2025 for Immunovant, down from $4.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $15.5 million in Q1 2024 and bottomed at -$17.3 million in Q2 2023.
  • Average Change in Accured Expenses over 5 years is $771176.5, with a median of $1.9 million recorded in 2021.
  • The largest annual shift saw Change in Accured Expenses surged 3253.57% in 2021 before it crashed 573.27% in 2022.
  • Immunovant's Change in Accured Expenses stood at $8.3 million in 2021, then crashed by 68.21% to $2.6 million in 2022, then tumbled by 302.77% to -$5.3 million in 2023, then surged by 177.6% to $4.1 million in 2024, then crashed by 269.34% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Change in Accured Expenses are -$7.0 million (Q1 2025), $4.1 million (Q4 2024), and $10.7 million (Q3 2024).